Gossamer Bio
GOSS

$1.12

5.35%

Market Cap: 253M

About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Employees: 135

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 10 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 15

21% more capital invested

Capital invested by funds: $193M [Q4 2023] → $234M (+$40.9M) [Q1 2024]

12% more funds holding

Funds holding: 97 [Q4 2023] → 109 (+12) [Q1 2024]

2% more call options, than puts

Call options by funds: $663K | Put options by funds: $650K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]

5.44% less ownership

Funds ownership: 93.12% [Q4 2023] → 87.68% (-5.44%) [Q1 2024]

19% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 32

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$4

257%

upside

Avg. target

$8.40

650%

upside

High target

$15

1,239%

upside

10 analyst ratings

10 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Andreas Argyrides	704%upside $9	Outperform Initiated	25 Jun 2024
Goldman Sachs Paul Choi	614%upside $8	Buy Maintained	17 Jun 2024
HC Wainwright & Co. Patrick Trucchio	793%upside $10	Buy Reiterated	20 May 2024
Wedbush Laura Chico	257%upside $4	Outperform Reiterated	8 May 2024
HC Wainwright & Co. Patrick Trucchio	793%upside $10	Buy Reiterated	6 May 2024

See Analyst Rankings

Financial journalist opinion

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.

The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

Do you have any penny stocks in your portfolio? If you don't, you might want to consider it with any speculative money sitting on the sidelines.

The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5, 2024, to one new non-executive employee of non-qualified stock option aw.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present updated seralutinib TORREY open-label extension data at the American Thoracic Society 2024 International Conference, which takes place May 17-22 in San Diego, California. Details.

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 8, 2024, to three new non-executive employees of non-qualified stock option.

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2024, and provided a business update. “Our team at Gossamer continues to execute on our mission to enhance the live.

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions.

Gossamer Bio and Chiesi Group to collaborate for blood pressure treatment

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

SAN DIEGO, Calif. & PARMA, Italy--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (“Gossamer”) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, and Chiesi Farmaceutici S.p.A (“Chiesi Group”), an international, research-focused biopharmaceutical group, today announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib. This glob.

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the publication of its TORREY Phase 2 study manuscript in the Lancet Respiratory Medicine journal. The paper, titled "Seralutinib in Adults with Pulmonary Arterial Hypertensio.

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced the appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors. Dr. Nathan is Medical Director of Inova's Advanced Lung Disease Program and Lung Transpla.

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D.

See News Rankings